{"id":340625,"date":"2026-11-05T13:41:28","date_gmt":"2026-11-05T08:11:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=340625"},"modified":"2026-11-05T13:41:28","modified_gmt":"2026-11-05T08:11:28","slug":"sakar-healthcare-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/","title":{"rendered":"Sakar Healthcare Share Price Target 2027: Can It Reach Rs 1,408? Base Case at Rs 1,175"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Sakar Healthcare share price Rs 1,014.90 (5 November 2026). Base target Rs 1,175, bull Rs 1,408, downside risk Rs 784. PE 50.83. 52W range Rs 352.50 to Rs 1,229.85.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Sakar Healthcare share price target for 2027 is Rs 1,175, about 15.8% above the current price of Rs 1,014.90. The bull case is Rs 1,408, and the downside risk level, which is not a target, is Rs 784. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 56.0%, with the stock holding its PE of 50.83. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a Sakar Healthcare target price for 2027 should start with where the stock sits today. At Rs 1,014.90 on 5 November 2026, it is 17.5% below its 52-week high of Rs 1,229.85 and 187.9% above its 52-week low of Rs 352.50. That range spans 249% from low to high, so the entry point matters as much as the Sakar Healthcare price forecast itself.<\/p>\n<p>This article builds the Sakar Healthcare share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=sakar-healthcare-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Sakar_Healthcare_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Sakar Healthcare Stock Analysis: Company Overview and Key Stats\">Sakar Healthcare Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Why_Is_Sakar_Healthcare_Share_Price_Target_Set_at_Rs_1175_for_2027\" title=\"Why Is Sakar Healthcare Share Price Target Set at Rs 1,175 for 2027?\">Why Is Sakar Healthcare Share Price Target Set at Rs 1,175 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Earnings_Growth_Behind_the_Sakar_Healthcare_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Sakar Healthcare Target Price: Five Years of Results\">Earnings Growth Behind the Sakar Healthcare Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Valuation_Check_for_the_Sakar_Healthcare_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Sakar Healthcare Stock Target: PE, Price to Book and ROE\">Valuation Check for the Sakar Healthcare Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Sakar_Healthcare_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Sakar Healthcare Share Price Targets for the Short Term and 12 Months\">Sakar Healthcare Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Short_Term_Sakar_Healthcare_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Sakar Healthcare Stock Target Levels: Technical Setup\">Short Term Sakar Healthcare Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#12_Month_Sakar_Healthcare_Target_Price_for_2027\" title=\"12 Month Sakar Healthcare Target Price for 2027\">12 Month Sakar Healthcare Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Sakar_Healthcare_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Sakar Healthcare Target Price\">How EPS Growth and PE Multiple Change the Sakar Healthcare Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Sakar_Healthcare_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Sakar Healthcare Stock Target in 2027\">Bull Case and Downside Risk for Sakar Healthcare Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Bull_Case_Rs_1408\" title=\"Bull Case Rs 1,408\">Bull Case Rs 1,408<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Downside_Risk_Level_Rs_784\" title=\"Downside Risk Level Rs 784\">Downside Risk Level Rs 784<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Key_Risks_to_the_Sakar_Healthcare_Target_Price_for_2027\" title=\"Key Risks to the Sakar Healthcare Target Price for 2027\">Key Risks to the Sakar Healthcare Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Sakar_Healthcare_Price_Target\" title=\"Growth Slowdown Risk for the Sakar Healthcare Price Target\">Growth Slowdown Risk for the Sakar Healthcare Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#How_to_Invest_in_Sakar_Healthcare\" title=\"How to Invest in Sakar Healthcare\">How to Invest in Sakar Healthcare<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#FAQs_on_Sakar_Healthcare_Share_Price_Target_2027\" title=\"FAQs on Sakar Healthcare Share Price Target 2027\">FAQs on Sakar Healthcare Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#What_is_the_Sakar_Healthcare_share_price_target_for_2027\" title=\"What is the Sakar Healthcare share price target for 2027?\">What is the Sakar Healthcare share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#What_is_the_Sakar_Healthcare_share_price_today\" title=\"What is the Sakar Healthcare share price today?\">What is the Sakar Healthcare share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Is_Sakar_Healthcare_a_buy_or_sell_at_the_current_price\" title=\"Is Sakar Healthcare a buy or sell at the current price?\">Is Sakar Healthcare a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Sakar_Healthcare_shares\" title=\"What are the bull case target and downside risk level for Sakar Healthcare shares?\">What are the bull case target and downside risk level for Sakar Healthcare shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#What_are_the_main_risks_to_the_Sakar_Healthcare_price_target\" title=\"What are the main risks to the Sakar Healthcare price target?\">What are the main risks to the Sakar Healthcare price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#What_is_the_PE_ratio_of_Sakar_Healthcare_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Sakar Healthcare and how does it compare with the industry?\">What is the PE ratio of Sakar Healthcare and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#Who_owns_Sakar_Healthcare_and_what_is_the_promoter_holding\" title=\"Who owns Sakar Healthcare, and what is the promoter holding?\">Who owns Sakar Healthcare, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/sakar-healthcare-share-price-target-2027\/#What_were_Sakar_Healthcares_latest_quarterly_results\" title=\"What were Sakar Healthcare&#8217;s latest quarterly results?\">What were Sakar Healthcare&#8217;s latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Sakar_Healthcare_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Sakar Healthcare Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sakar Healthcare (NSE: SAKAR) has a market capitalisation of Rs 2,179 crore. In FY26 it reported revenue of Rs 254.02 crore and net profit of Rs 30.48 crore. The table collects the figures the Sakar Healthcare share price target is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/sakar\/sakar-healthcare-ltd-share-price-today\">Sakar Healthcare<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>SAKAR<\/td>\n<\/tr>\n<tr>\n<td>CMP (5 November 2026)<\/td>\n<td>Rs 1,014.90<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 1,229.85<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 352.50<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 2,179 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>50.83<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>38.06<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>6.30<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>12.39%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.13<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 19.27<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.00%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 1,175<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 1,408<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 784<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Sakar_Healthcare_Share_Price_Target_Set_at_Rs_1175_for_2027\"><\/span><strong>Why Is Sakar Healthcare Share Price Target Set at Rs 1,175 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The arithmetic is short. Trailing EPS of Rs 19.27 grown for one year gives a forward EPS estimate of Rs 23.12, and multiplying it by the unchanged PE of 50.83 gives the Rs 1,175 base-case Sakar Healthcare stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Sakar_Healthcare_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Sakar Healthcare Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sakar Healthcare grew revenue from Rs 130.40 crore in FY22 to Rs 254.02 crore in FY26, a compound annual growth rate of 18.1%. Net profit grew faster, from Rs 15.24 crore to Rs 30.48 crore (18.9% a year), which shows margin gains did part of the work and not just higher sales.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>130.40<\/td>\n<td>15.24<\/td>\n<td>9.96<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>138.03<\/td>\n<td>12.76<\/td>\n<td>6.75<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>156.53<\/td>\n<td>11.67<\/td>\n<td>5.63<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>178.90<\/td>\n<td>17.50<\/td>\n<td>7.95<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>254.02<\/td>\n<td>30.48<\/td>\n<td>13.70<\/td>\n<td>0.00<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 42.0%, faster than the four-year average of 18.1%, and net profit moved up 74.2%. EPS rose from Rs 5.63 in FY24 to Rs 13.70 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sakar Healthcare converted 12.0% of FY26 revenue into net profit, against 9.8% in FY25, within a five-year range of 7.5% to 12.0%. EBITDA margin was 28.0% in FY26 versus 28.5% in FY25.<\/p>\n<p>In the September 2026 quarter, revenue was Rs 87.70 crore, up 49.2% from the same quarter a year earlier, while net profit of Rs 11.31 crore was up 149.1%. EBITDA came in at Rs 24.62 crore, up 96.0% year on year. The next quarterly result is the first test of whether the earnings assumption holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.13, and shareholders&#8217; equity grew from Rs 127.45 crore in FY22 to Rs 324.45 crore in FY26. Operating cash flow in FY26 was Rs 49.26 crore against capital expenditure of Rs 28.35 crore, leaving free cash flow of Rs 20.91 crore, or 1.0% of the current market capitalisation. In FY25 free cash flow was Rs 1.75 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Sakar_Healthcare_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Sakar Healthcare Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 50.83 against an industry PE of 38.06, Sakar Healthcare trades at a premium to its industry. Price to book is 6.30 on a book value of Rs 155.50 per share, and return on equity is 12.39%. A PE of 50.83 equals an earnings yield of 2.0%, and the FY26 dividend of Rs 0.00 per share gives a yield of 0.00%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 51.70% of Sakar Healthcare in September 2026, and promoter holding fell from 52.86% in September 2025 to 51.70% in September 2026. Foreign institutional investors (FII) held 12.34% and domestic institutions (DII) held 11.92%, which puts total institutional holding at 24.26%. FII holding fell from 13.31% in September 2025 to 12.34% in September 2026. Public shareholders own the remaining 24.04%. A meaningful institutional holding adds a layer of research coverage and trading depth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sakar_Healthcare_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Sakar Healthcare Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Sakar_Healthcare_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Sakar Healthcare Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 1,014.90 on 5 November 2026, Sakar Healthcare trades below its 50-day simple moving average of Rs 1,022.20 and above its 200-day exponential moving average of Rs 796.57. The 14-day RSI reads 52.5, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 1,022.20 (50-day simple moving average) and the nearest support is Rs 796.57 (200-day exponential moving average). A sustained move above Rs 1,022.20 would improve the short-term setup, while a close below Rs 796.57 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Sakar_Healthcare_Target_Price_for_2027\"><\/span><strong>12 Month Sakar Healthcare Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target of Rs 1,175 means a move of 15.8% up from Rs 1,014.90 over the next 12 months. It would still leave the stock 4.5% below its 52-week high of Rs 1,229.85. Anyone checking the Sakar Healthcare share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Sakar_Healthcare_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Sakar Healthcare Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 40.66<\/th>\n<th>PE 50.83<\/th>\n<th>PE 58.45<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 19.27)<\/td>\n<td>Rs 784<\/td>\n<td>Rs 979<\/td>\n<td>Rs 1,126<\/td>\n<\/tr>\n<tr>\n<td>20.0% (EPS Rs 23.12)<\/td>\n<td>Rs 940<\/td>\n<td>Rs 1,175<\/td>\n<td>Rs 1,351<\/td>\n<\/tr>\n<tr>\n<td>25.0% (EPS Rs 24.09)<\/td>\n<td>Rs 979<\/td>\n<td>Rs 1,224<\/td>\n<td>Rs 1,408<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Sakar Healthcare price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Sakar_Healthcare_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Sakar Healthcare Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_1408\"><\/span><strong>Bull Case Rs 1,408<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Sakar Healthcare price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 24.09, and a PE multiple that rises 15% to 58.45. That gives Rs 1,408, 38.7% above the current price and above the 52-week high of Rs 1,229.85, so the stock would have to set a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_784\"><\/span><strong>Downside Risk Level Rs 784<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 19.27 and the PE falls 20% to 40.66. That gives Rs 784, 22.8% below the current price and above the 52-week low of Rs 352.50.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>25.0%<\/td>\n<td>58.45<\/td>\n<td>Rs 1,408<\/td>\n<td>+38.7%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>20.0%<\/td>\n<td>50.83<\/td>\n<td>Rs 1,175<\/td>\n<td>+15.8%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>40.66<\/td>\n<td>Rs 784<\/td>\n<td>-22.8%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Sakar_Healthcare_Target_Price_for_2027\"><\/span><strong>Key Risks to the Sakar Healthcare Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Sakar_Healthcare_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Sakar Healthcare Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the September 2026 quarter was up 49.2% year on year, and FY26 revenue growth was 42.0%. If growth slows from here, the EPS estimate behind the Sakar Healthcare stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sakar Healthcare has a market capitalisation of Rs 2,179 crore. Institutional holding is 24.26%, and promoters hold 51.70%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 12.0% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 50.83 versus an industry PE of 38.06, a de-rating toward the downside-risk PE of 40.66 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Technical indicators add short-term risk: the 14-day RSI is 52.5 and the MACD sits above its signal line. A broad fall in the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> or the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> can override company fundamentals for weeks at a time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Sakar_Healthcare\"><\/span><strong>How to Invest in Sakar Healthcare<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any Sakar Healthcare share price target is only as current as the data behind it, and the data here is as of 5 November 2026, so refresh the Rs 1,014.90 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Sakar Healthcare&#8217;s PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Sakar Healthcare fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three Sakar Healthcare target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Sakar Healthcare live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Sakar Healthcare share price target for 2027 is Rs 1,175 in the base case, with Rs 1,408 as the bull case. The support for that view is arithmetic you can check: EPS grew 56.0% a year over FY24 to FY26, and the stock trades at a PE of 50.83. The risks are equally concrete, including a PE of 50.83 that sits above the industry PE of 38.06 and a downside scenario that cuts the price 23% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Sakar_Healthcare_Share_Price_Target_2027\"><\/span><strong>FAQs on Sakar Healthcare Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Sakar_Healthcare_share_price_target_for_2027\"><\/span><strong>What is the Sakar Healthcare share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Sakar Healthcare share price target for 2027 is Rs 1,175, which is 15.8% above the price of Rs 1,014.90 on 5 November 2026. The bull case is Rs 1,408 and the downside risk level, which is not a target, is Rs 784. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Sakar_Healthcare_share_price_today\"><\/span><strong>What is the Sakar Healthcare share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 5 November 2026, 11:37 AM IST, Sakar Healthcare (NSE: SAKAR) trades at Rs 1,014.90, up 3.61% on the day. That is 17.5% below the 52-week high of Rs 1,229.85 and 187.9% above the 52-week low of Rs 352.50. The market capitalisation of Rs 2,179 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Sakar_Healthcare_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Sakar Healthcare a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data points both ways. On the positive side, EPS has grown 56.0% a year over FY24 to FY26 and the base case implies 15.8% upside; on the cautious side, the PE of 50.83 is above the industry PE of 38.06, and the downside risk level of Rs 784 is 23% below the current price. Whether Sakar Healthcare fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Sakar_Healthcare_shares\"><\/span><strong>What are the bull case target and downside risk level for Sakar Healthcare shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case in the Sakar Healthcare share price target for 2027 is Rs 1,408, which assumes 25.0% EPS growth and a PE of 58.45, a 15% re-rating from today&#8217;s multiple. That is 38.7% above the current price and above the 52-week high of Rs 1,229.85, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 784, which assumes flat EPS and a PE of 40.66, 20% lower than today. It sits 22.8% below the current price and above the 52-week low of Rs 352.50, and it marks a risk to watch, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Sakar_Healthcare_price_target\"><\/span><strong>What are the main risks to the Sakar Healthcare price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Four risks matter most for the Sakar Healthcare share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 2,179 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 40.66 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Sakar_Healthcare_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Sakar Healthcare and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Sakar Healthcare is 50.83, against an industry PE of 38.06, which is a premium to the industry. Price to book is 6.30 and return on equity is 12.39%, and the PE equals an earnings yield of 2.0%. The base case holds the PE unchanged, so the Sakar Healthcare share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Sakar_Healthcare_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Sakar Healthcare, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 51.70% of Sakar Healthcare in September 2026. FII held 12.34%, DII held 11.92% and the public held 24.04%. Together the two institutional groups hold 24.26%. Shareholding is filed every quarter, so it is worth rechecking after each result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Sakar_Healthcares_latest_quarterly_results\"><\/span><strong>What were Sakar Healthcare&#8217;s latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the September 2026 quarter, Sakar Healthcare reported revenue of Rs 87.70 crore (up 49.2% year on year) and net profit of Rs 11.31 crore (up 149.1%). For comparison, FY26 full-year revenue growth was 42.0% and net profit moved up 74.2%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Sakar Healthcare share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Sakar Healthcare share price target for 2027 is Rs 1,175, which is 15.8% above the price of Rs 1,014.90 on 5 November 2026. The bull case is Rs 1,408 and the downside risk level, which is not a target, is Rs 784. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.\"}},{\"@type\":\"Question\",\"name\":\"What is the Sakar Healthcare share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 5 November 2026, 11:37 AM IST, Sakar Healthcare (NSE: SAKAR) trades at Rs 1,014.90, up 3.61% on the day. That is 17.5% below the 52-week high of Rs 1,229.85 and 187.9% above the 52-week low of Rs 352.50. The market capitalisation of Rs 2,179 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.\"}},{\"@type\":\"Question\",\"name\":\"Is Sakar Healthcare a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data points both ways. On the positive side, EPS has grown 56.0% a year over FY24 to FY26 and the base case implies 15.8% upside; on the cautious side, the PE of 50.83 is above the industry PE of 38.06, and the downside risk level of Rs 784 is 23% below the current price. Whether Sakar Healthcare fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Sakar Healthcare shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case in the Sakar Healthcare share price target for 2027 is Rs 1,408, which assumes 25.0% EPS growth and a PE of 58.45, a 15% re-rating from today's multiple. That is 38.7% above the current price and above the 52-week high of Rs 1,229.85, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 784, which assumes flat EPS and a PE of 40.66, 20% lower than today. It sits 22.8% below the current price and above the 52-week low of Rs 352.50, and it marks a risk to watch, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Sakar Healthcare price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four risks matter most for the Sakar Healthcare share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 2,179 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 40.66 would cut the price even if earnings hold.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Sakar Healthcare and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Sakar Healthcare is 50.83, against an industry PE of 38.06, which is a premium to the industry. Price to book is 6.30 and return on equity is 12.39%, and the PE equals an earnings yield of 2.0%. The base case holds the PE unchanged, so the Sakar Healthcare share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Sakar Healthcare, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 51.70% of Sakar Healthcare in September 2026. FII held 12.34%, DII held 11.92% and the public held 24.04%. Together the two institutional groups hold 24.26%. Shareholding is filed every quarter, so it is worth rechecking after each result.\"}},{\"@type\":\"Question\",\"name\":\"What were Sakar Healthcare's latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the September 2026 quarter, Sakar Healthcare reported revenue of Rs 87.70 crore (up 49.2% year on year) and net profit of Rs 11.31 crore (up 149.1%). For comparison, FY26 full-year revenue growth was 42.0% and net profit moved up 74.2%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sakar Healthcare share price target 2027: base Rs 1,175, bull Rs 1,408, downside risk level Rs 784, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":38,"featured_media":340624,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-340625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["340624"],"rank_math_title":["Sakar Healthcare Share Price Target 2027: 15.8% Upside and Risks"],"rank_math_description":["The Sakar Healthcare share price target for 2027 is Rs 1,175 versus Rs 1,014.90 today. Bull case, downside risk, earnings trend and risks explained. November 2026."],"rank_math_focus_keyword":["Sakar Healthcare share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/sakar-healthcare-share-price-target-2027-can-it-reach-rs-1-408-base-case-at-rs-1.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=340625"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340625\/revisions"}],"predecessor-version":[{"id":340626,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340625\/revisions\/340626"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/340624"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=340625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=340625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=340625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}